ClinicalTrials.gg
RecruitingNCT05523609Updated Dec 1, 2023

Vitamin D and Calcium Supplementation in Breast Cancer

A Phase 2/3 interventional study of Letrozole 2.5mg and Letrozole + vitamin D3 and calcium in Breast Cancer, sponsored by Tanta University. Recruiting at 1 site in Egypt. Open to female participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2023-12-01.

Sponsored by Tanta University · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2024, 2 years 2 months ago, but the record still lists the study as recruiting.
  • Started Nov 2022; still recruiting 4 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
50 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 162 studies testing letrozole in Breast Neoplasms — 22 open to participants now, 39 under way, 11 of them phase 3. Letrozole · Breast Neoplasms.

Planned enrollment
111th of 159
40 · median 95
Started
2022
with 6 others
Phase 2/3
4 of 162
1 open now
Primary completion
2024-09
later than 11 of 38 live
Registered
147th of 162
by date

Among the 162 studies testing letrozole in Breast Neoplasms, this one is the 111th largest by planned enrollment of the 159 interventional ones that give a count, is one of 7 that started in 2022, is one of 4 in phase 2/3, reaches primary completion later than 11 of the 38 other live ones, and was the 147th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

22 of the 162 studies testing letrozole in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About letrozole

Letrozole: first FDA approval 1997 (FEMARA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 50 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 162 studies testing letrozole in Breast Neoplasms, or all of them as a file.
02

Study summary

This study aims at assessing the vitamin Dstatus in breast cancer patients who receive letrozole for more than two months and to evaluate effects of vitamin D3 and calcium supplementation on arthalgia caused by letrozole on these patients.

Read the detailed description

Background: Vitamin D deficiency (\< 10 ng/mL) and insufficiency (10-30 ng/mL) may contribute to musculoskeletal symptoms observed in patients taking letrozole. This study was undertaken to assess the vitamin D status in breast cancer patients who received letrozole for > 6 months and to evaluate the effects of vitamin D3 and calcium supplementation on them.

Methods: Forty breast cancer patients were included. They were divided into 2 equal groups: Control group received Letrozole only, and VitD/Ca group received Letrozole in addition to 2000 IU vitamin D3 and 1000 mg of calcium per day for 12 weeks. Baseline serum 25-hydroxy vitamin D concentrations were assayed and standard health assessment questionnaire was completed to assess the disability caused by musculoskeletal symptoms.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Newly diagnosed breast cancer patients.
  • hormone receptor positive.
  • Patients receiving letrozole for more than two months
  • Gender: Female.
  • Age: ≥ 50 years old.

Exclusion criteria

Exclusion Criteria:

  • Patients with bone .
  • History of renal stones.
  • Serum calcium >11mg/L.
  • Patients with renal insufficiency.
  • Patients taking hormone replacement therapy.
  • Second .
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Control Group

    20 patients will receive Letrozole only for 12 weeks.

    Drug: Letrozole 2.5mg

  • Experimental
    VitD/Ca group

    20 patients will receive Letrozole in addition to 2000 IU vitamin D3 and 1000 mg of calcium per day for 12 weeks.

    Drug: Letrozole + vitamin D3 and calcium

Interventions

06

What researchers measure

Primary outcomes

  1. Osteocalcin level

    Osteocalcin level at base line and 12 weeks

    Time frame: 12 weeks

07

Study locations

1 of 1 sites recruiting
  • Tanta Cancer Center
    Tanta, El-Gharbia GHR, Egypt
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2022 (actual). Primary completion is estimated for Sep 2024, 22 months after the start.

Of 43 non-industry phase 2/3 interventional studies under Breast Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 91. This study's planned 22 months is below that.

Counting every sponsor, half of 56 studies reached it within 57 months; a quarter within 32 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2022
First posted
Aug 31, 2022
StartActual
Nov 1, 2022
Primary completionEst.
Sep 2024
CompletionEst.
Oct 2024
Last update
Dec 1, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05523609
Lead sponsor
Tanta University
Responsible party
Mai Abo Elyazeed Hassan Hamouda (Clinical Pharmacist, Tanta University) — Principal investigator
First posted
Aug 31, 2022
Start date
Nov 1, 2022
Primary completion
Sep 2024 (estimated)
Completion
Oct 2024 (estimated)
Last update
Dec 1, 2023

Study contacts

Mai A Elgebaly, Pharm D
Contact
dr.mai.elgebaly@gmail.com
01061412257 ext. 002
Sahar K Hegazy, Professor
study director · Head of clinical Pharmacy Department

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Letrozole · Cholecalciferol · Calcium

Start the discussion